The Area Under the ROC Curve as a Measure of Clustering Quality

The Area Under the the Receiver Operating Characteristics (ROC) Curve, referred to as AUC, is a well-known performance measure in the supervised learning domain. Due to its compelling features, it has been employed in a number of studies to evaluate and compare the performance of different classifiers. In this work, we explore AUC as a performance measure in the unsupervised learning domain, more specifically, in the context of cluster analysis. In particular, we elaborate on the use of AUC as an internal/relative measure of clustering quality, which we refer to as Area Under the Curve for Clustering (AUCC). We show that the AUCC of a given candidate clustering solution has an expected value under a null model of random clustering solutions, regardless of the size of the dataset and, more importantly, regardless of the number or the (im)balance of clusters under evaluation. In addition, we elaborate on the fact that, in the context of internal/relative clustering validation as we consider, AUCC is actually a linear transformation of the Gamma criterion from Baker and Hubert (1975), for which we also formally derive a theoretical expected value for chance clusterings. We also discuss the computational complexity of these criteria and show that, while an ordinary implementation of Gamma can be computationally prohibitive and impractical for most real applications of cluster analysis, its equivalence with AUCC actually unveils a much more efficient algorithmic procedure. Our theoretical findings are supported by experimental results. These results show that, in addition to an effective and robust quantitative evaluation provided by AUCC, visual inspection of the ROC curves themselves can be useful to further assess a candidate clustering solution from a broader, qualitative perspective as well.Comment: 37 pages, 5 figures, submitted for publicatio

Side-lobe level reduction in bio-inspired optical phased-array antennas

COORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL DE NÍVEL SUPERIOR - CAPESFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPCONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQPhased arrays are expected to play a critical role in visible and infrared wireless systems. Their improved performance compared to single element antennas finds uses in communications, imaging, and sensing. However, fabrication of photonic antennas and their feeding network require long element separation, leading to the appearance of secondary radiation lobes and, consequently, crosstalk and interference. In this work, we experimentally show that by arranging the elements according to the Fermat's spiral, the side lobe level (SLL) can be reduced. This reduction is proved in a CMOS-compatible 8-element array, revealing a SLL decrement of 0.9 dB. Arrays with larger numbers of elements and inter-element spacing are demonstrated through a spatial light modulator (SLM) and an SLL drop of 6.9 dB is measured for a 64-element array. The reduced SLL, consequently, makes the proposed approach a promising candidate for applications in which antenna gain, power loss, or information security are key requirements.25243010530114COORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL DE NÍVEL SUPERIOR - CAPESFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPCONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQCOORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL DE NÍVEL SUPERIOR - CAPESFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPCONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQSem informação08/57857-22013/20180-32015/04113-0574017/2008-9446746/2014-

Phylogeny of Murray Valley encephalitis virus in Australia and Papua New Guinea

Abstract Objective To study the genetic diversity of Murray Valley encephalitis virus (MVEV) in Australia and Papua New Guinea. Methods MVEV envelope gene sequences were aligned using Clustal X and manual editing was performed with Bioedit. ModelTest v. 3.7 was used to select the simplest evolutionary model that adequately fitted the sequence data. Maximum likelihood analysis was performed using PhyML. The phylogenetic signal of the dataset was investigated by the likelihood mapping analysis. The Bayesian phylogenetic tree was built using BEAST. Results The phylogenetic trees showed two main clades. The clade Ⅰ including eight strains isolated from West Australia. The clade Ⅱ was characterized by at least four epidemic entries, three of which localized in Northern West Australia and one in Papua New Guinea. The estimated mean evolutionary rate value of the MVEV envelope gene was 0.407 × 10−3 substitution/site/year (95% HPD: 0.623 × 10−4–0.780 × 10−3). Population dynamics defines a relative constant population until the year 2000, when a reduction occurred, probably due to a bottleneck. Conclusions This study has been useful in supporting the probable connection between climate changes and viral evolution also by the vector point of view; multidisciplinary monitoring studies are important to prevent new viral epidemics inside and outside new endemic areas

Pallister–Killian syndrome: Cytogenetics and molecular investigations of mosaic tetrasomy 12p in prenatal chorionic villus and in amniocytes. Strategy of prenatal diagnosis

Abstract Objective Pallister–Killian syndrome (PKS) is a rare, sporadic genetic disorder caused by mosaic tetrasomy of the short arm of chromosome 12 (12p). Clinically, PKS is characterized by several systemic abnormalities, such as intellectual impairment, hearing loss, epilepsy, hypotonia, craniofacial dysmorphism, pigmentary skin anomalies, epilepsy, and a variety of congenital malformations. Prenatally, PKS can be suspected in the presence of ultrasound anomalies: diaphragmatic hernia, rhizomelic micromelia, hydrops fetalis, fetal overweight, ventriculomegaly in the central nervous system, congenital heart defects, or absent visualization of the stomach. In all these cases, a detailed genetic study is required. PKS is diagnosed by prenatal genetic analysis through chorionic villus sampling, genetic amniocentesis, and cordocentesis. Case Report We report two cases of PKS with prenatal diagnosis of isochromosome 12p made by cytogenetic studies. The first case is of a 36-year-old pregnant woman who underwent genetic chorionic villus sampling at 13 th weeks of gestation after 1 st trimester prenatal ultrasound revealed clinical features of PKS: flat nasal bridge and fetal hydrops. The second case is of a 32-year-old pregnant woman with genetic amniocentesis at 17 th weeks of gestation that showed mos46,XX[21]/47,XX,+i(12p) associated to PKS. Conclusion New molecular cytogenetic techniques array comparative genomic hybridization and fluorescence in-situ hybridization in association with conventional karyotype are pivotal innovative tools to search for chromosomic anomalies and for a complete prenatal diagnosis, especially in cases such as PKS where array comparative genomic hybridization analysis alone could not show mosaicism of i(12p)

Muon-electron conversion in strange quark sea

We study nuclear muon-electron (mu-e) conversion in the general framework of effective Lagrangian approach without referring to any specific realization of the physics beyond the standard model (SM) responsible for lepton flavor violation (LFV). All the possible types of short range interactions (non-photonic mechanisms), i.e. (pseudo-)scalar, (axial-)vector and tensor, are included in our formalism. We show that the mu-e conversion in the strange nucleon sea via the scalar interactions is comparable with that in the valence quarks. This provides an insight into the strange quark couplings beyond the SM. From the available experimental data on mu-e conversion and expected sensitivities of planned experiments we derived upper bounds on the generic LFV - parameters of mu-e conversion sensitive to the relevant u-,d- and s-quark couplings.Comment: 11 pages, 1 figure, minor changes matching published versio

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema

The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this consensus provides clinicians with an overview of the diagnosis and treatment of scleromyxoedema and scleroedema (of Buschke)

EULAR recommendations for the treatment of systemic sclerosis: 2023 update

OBJECTIVES: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. METHODS: An international task force was convened in line with EULAR standard operating procedures. A nominal group technique exercise was performed in two rounds to define questions underpinning a subsequent systematic literature review. The evidence derived was discussed and overarching principles, recommendations and future research agenda were iteratively developed with voting rounds. RESULTS: The task force agreed on 22 recommendations covering 8 clinical/organ domains including Raynaud's phenomenon, digital ulcers, pulmonary arterial hypertension, scleroderma renal crisis, skin fibrosis, interstitial lung disease (ILD), gastrointestinal manifestations and arthritis. Most new recommendations are related to skin fibrosis and ILD. These included novel recommendations for the use of mycophenolate mofetil, nintedanib, rituximab and tocilizumab for the treatment of these crucial disease manifestations. The recommendations also included first-line and second-line interventions, providing increased utility for rheumatology practitioners. Important additions to the future research agenda included consideration of novel interventions for the management of vascular, musculoskeletal and gastrointestinal manifestations and calcinosis, as well as for the local management of digital ulcers. CONCLUSION: These updated recommendations include the first set of synthetic and biological targeted therapies recommended for key fibrotic manifestations of SSc as well as first-line combination treatment for newly diagnosed pulmonary artery hypertension and prioritise a new research agenda for the coming years

Effectiveness and safety of tocilizumab in patients with systemic sclerosis : a propensity score matched controlled observational study of the EUSTAR cohort

Objectives Tocilizumab showed trends for improving skin fibrosis and prevented progression of lung fibrosis in systemic sclerosis (SSc) in randomised controlled clinical trials. We aimed to assess safety and effectiveness of tocilizumab in a real-life setting using the European Scleroderma Trial and Research (EUSTAR) database. Methods Patients with SSc fulfilling the American College of Rheumatology (ACR)/EULAR 2013 classification criteria, with baseline and follow-up visits at 12±3 months, receiving tocilizumab or standard of care as the control group, were selected. Propensity score matching was applied. Primary endpoints were the modified Rodnan skin score (mRSS) and FVC at 12±3 months compared between the groups. Secondary endpoints were the percentage of progressive/regressive patients for skin and lung at 12±3 months. Results Ninety-three patients with SSc treated with tocilizumab and 3180 patients with SSc with standard of care fulfilled the inclusion criteria. Comparison between groups did not show significant differences, but favoured tocilizumab across all predefined primary and secondary endpoints: mRSS was lower in the tocilizumab group (difference -1.0, 95% CI -3.7 to 1.8, p=0.48). Similarly, FVC % predicted was higher in the tocilizumab group (difference 1.5 (-6.1 to 9.1), p=0.70). The percentage of progressive/regressive patients favoured tocilizumab over controls. These results were robust regarding the sensitivity analyses. Safety analysis confirmed previously reported adverse event profiles. Conclusion Although this large, observational, controlled, real-life EUSTAR study did not show significant effectiveness of tocilizumab on skin and lung fibrosis, the consistency of direction of all predefined endpoints generates hypothesis for potential effectiveness in a broader SSc population